

RFQ Number: RFQ-NCI-10007-AS  
Amendment One (1)

Office of Acquisitions  
National Cancer Institute

Date of Issuance: February 19, 2010

The above numbered Request for Quotation (RFQ) is amended as set forth below. The hour and dates specified for receipt of responses remains unchanged.

1. The subject RFQ is hereby revised to procure a limited amount of normal tissue in addition to procuring cancer tissue. The main intent of the RFQ is still the procurement of cancer tissue. Attached is a spreadsheet entitled "Methylation normal controls – 2/16/10" mapping cancer tissue and normal tissue. Responses must clearly identify cancer tissue and normal tissue. Awards for normal tissue will be based upon technical merit, programmatic needs, and availability of funds.
2. For all tissue samples proposed, offerors must identify those samples that are located in a foreign country (non-United States country) or that came from a foreign country and identify the country by name.
3. All responses, documentation, correspondence, and deliverables must be in English, including all Tier 1 and Tier 2 data.
4. Attached is a sample template that offerors can use to format their response (See attachment labeled "RFQ Response Template FINAL- 2-16-10"). Please note that use of this format is not mandatory.
5. For all solid tumor types, samples with blood as the normal control will be prioritized in terms of award.
6. Section 2.1.3.1 Biospecimen Criteria for TCGA is hereby revised as follows:
  - a. Under the section covering Primary Tumors – the third bullet is revised to read as follows:  
"Sufficient tissue to yield 15ug of DNA and 15ug of RNA (this is typically 100-150mg of tissue)."
  - b. Under the section covering Normal Tissue – the second bullet and third bullets are hereby revised to read as follows:
    - "The sample shall be sufficient to yield at least 15micrograms of DNA
    - If previously extracted DNA is provided, 15 micrograms should be prepared...."

The remainder of Section 2.1.3.1. is unchanged.
7. The following is hereby added: "Invoices from the Tissue Source Sites must be received by the Government within sixty (60) calendar days of written confirmation from the appropriate Biospecimen Core Resource (BCR) that a payment milestone has been achieved according to the payment schedule defined in Section 2.2. of the Statement of Work."

**ALL OTHER RFQ INFORMATION REMAINS UNCHANGED.**



## **5. Informed Consent and Institutional Review Board (IRB) Status**

Two items are required:

- 1) Respondents should describe the status of IRB of the protocol(s) used to acquire samples for this response; specifically state whether the protocol(s) under which these materials were collected is still open.
- 2) Provide documentation of Principal Investigator's IRB approval to participate in TCGA, whether a new protocol, administrative approval, waiver, or otherwise.

## **6. Clinical Data Element Collection and Follow-Up**

Describe the ability to provide the surgical pathology report, clinical data and follow-up at 6 month intervals, as outlined in the RFQ Section 2.1.4 and as enumerated in greater, per cancer detail in the TCGA Disease Working Group clinical data specifications. Specifically indicate (and enumerate the number of such cases) you will not be able to submit 100% of the minimally required enrollment data elements and / or will not be able to determine vital status/date of death on every case. Note that all data and documentation must be provided in English.

## **7. Material Transfer Agreement (MTA)**

Specifically state whether the MTA cover memo has been fully reviewed by relevant institutional authorities and that all the policy terms in the memo are acceptable to your institution. If discussions with a TCGA Biospecimen Core Resource (BCR) have begun, describe the status of the MTA agreement between your institution and the BCR.

## **8. Ability to Comply with ARRA Requirements.**

Respondents must clearly state their agreement to comply with ARRA terms as stated in the SOW.

## **9. Detailed Quotation**

Respondents should include the price per case. Note the price should:

- Not include the cost of shipping. This will be borne by the BCR.
- Be reflective of all your **new** locally incurred costs to provide these materials, including future costs, for example, collecting vital status on still living patients.
- Include any indirects
- Be subdivided by cancer, if the price will be different.
- For all samples, specify if the samples are located in a foreign country (any country that is not the United States) or came from a foreign country and specify the foreign country by name.

**Methylation Normal Control - 2/16/10**

<b>RFQ Number*</b>	<b>Organ System</b>	<b>Cancer Type</b>	<b>Non-Tumor Tissue Control (Preferably Histologically Normal, Age-Matched, and Spread Among Various Batches)</b>	<b>Easier Alternative</b>
RFQ-NCI-10006-AS	Breast	Breast ductal carcinoma	Breast	
RFQ-NCI-10006-AS		Breast lobular carcinoma	Breast	
RFQ-NCI-10007-AS	Central Nervous System (Brain)	Astrocytoma	Brain	
RFQ-NCI-10006-AS		Glioblastoma multiforme	Brain	
RFQ-NCI-10006-AS	Gastrointestinal	Colon adenocarcinoma	Colonic Mucosa (Both Distal and Proximal)	
RFQ-NCI-10007-AS		Hepatocellular carcinoma	Liver	
RFQ-NCI-10007-AS		Pancreatic ductal adenocarcinoma	Pancreas (Flash frozen to prevent DNA degradation)	
RFQ-NCI-10006-AS		Stomach adenocarcinoma	Gastric Mucosa (Both Distal and Proximal)	
RFQ-NCI-10008-AS		Cervical cancer squamous cell carcinoma	Cervix or Vaginal Mucosa	
RFQ-NCI-10008-AS & RFQ-NCI-10007AS	Gynecologic	Ovarian serous cystadenoma	Fallopian Tube	
RFQ-NCI-10007-AS		Uterine corpus endometrial carcinoma	Endometrium	
RFQ-NCI-10007-AS	Head and Neck	Head and neck squamous cell carcinoma	Oral Mucosa	Skin
RFQ-NCI-10009-AS		Thyroid follicular carcinoma	Thyroid	
RFQ-NCI-10009-AS		Thyroid papillary carcinoma	Thyroid	
RFQ-NCI-10009-AS	Hematologic	Acute myeloid leukemia	Normal Bone Marrow	Whole Blood
RFQ-NCI-10009-AS		Chronic lymphocytic leukemia	Sorted Lymphocytes	Spleen
RFQ-NCI-10009-AS		Diffuse large B-cell lymphoma	Sorted Lymphocytes	Spleen
RFQ-NCI-10009-AS		Multiple myeloma	Sorted Monocytes/Neutrophils	Spleen
RFQ-NCI-10009-AS		Non-Hodgkins lymphoma	Sorted Lymphocytes	Spleen
RFQ-NCI-10007-AS	Skin	Cutaneous melanoma	Nevus (Melanoma is difficult to find a suitable control)	Skin (poor control)
RFQ-NCI-10006-AS	Thoracic	Lung adenocarcinoma	Lung (Peripheral, Alveolar Epithelium)	
RFQ-NCI-10006-AS		Lung squamous cell carcinoma	Lung (Proximal, Bronchial Epithelium)	
RFQ-NCI-10008-AS	Urologic	Bladder urothelial carcinoma (papillary)	Bladder	
RFQ-NCI-10008-AS		Bladder urothelial carcinoma (nonpapillary)	Bladder	
RFQ-NCI-10008-AS		Kidney papillary carcinoma	Kidney	
RFQ-NCI-10008-AS		Prostate adenocarcinoma	Prostate	
RFQ-NCI-10008-AS		Renal cell carcinoma	Kidney	